CDK9 and B-cell chronic lymphocytic leukemia: A growing body of evidence suggests that the expression of CDK9 is elevated in malignant cells, such as chronic lymphocytic leukemia, multiple myeloma, breast cancer, and lung cancer cells (Franco et al., 2018).